# Seroprevalence of Hepatitis C in Ethiopia: First National Study Based on the 2016 Ethiopian Demographic and Health Survey

**Authors:** Getahun Molla Kassa, Atsbeha Gebreegziabxier Weldemariam, Saro Abdella Abrahim, Clare E. French, Dawit Wolday, Emebet Dagne, Andargachew Mulu, Aynishet Adane, Sarah K. Inglis, Andrew Radley, Geremew Tasew, Peter Vickerman, Elias Ali Yesuf, Ora Paltiel, Mesay Hailu, Wondwossen Amogne, John F. Dillon, Matthew Hickman, Aaron G. Lim, Josephine G. Walker, John F. Dillon, John F. Dillon, Wondwossen Amogne, Peter Vickerman, Matthew Hickman, Ora Paltiel, Dawit Wolday, Aynishet Adane, Saro Abdella, Zenahbezu Abay, Workagegnehu Hailu, Tadesse Awoke, Emebet Dagne, Elias Ali Yesuf, Josephine G. Walker, Aaron G. Lim, Clare E. French, Andargachew Mulu, Melaku Tileku Tamiru, Atsbeha Gebreegziabxier Weldemariam, Christie Cabral, Obsie Baissa, Elizabeth Speakman, Andrew Radley, Amy Malaguti, Sarah K. Inglis, Meseret Yohannes, Bruktait Taddele, Hagos Abraha, Mengistu Erkie, Tesfa Sewunet Alamneh, Getahun Molla Kassa

PMC · DOI: 10.1111/jvh.14037 · 2024-11-21

## TL;DR

This study finds that Hepatitis C is rare in Ethiopia's general population, with higher rates in specific groups like those in Afar region or with HIV.

## Contribution

The first national seroprevalence study of Hepatitis C in Ethiopia using a large demographic survey.

## Key findings

- Overall Hepatitis C seroprevalence in Ethiopia is 0.18%, much lower than previous estimates.
- Higher rates were found in the Afar region (0.92%) and among people living with HIV (0.62%).
- Screening the general population is not cost-effective; targeted screening is recommended.

## Abstract

Hepatitis C virus (HCV) is hypothesised to be a public health problem in Ethiopia, and systematic review evidence suggested 1%–3% seroprevalence. We aimed to estimate the seroprevalence of HCV overall and across regions of Ethiopia. We estimated HCV seroprevalence using the 2016 Ethiopian Demographic and Health Survey (EDHS‐2016). EDHS‐2016 is a nationwide household survey conducted using two‐stage cluster sampling methods. We tested all 26,753 samples from participating adult women (15–49 years) and men (15–59 years) using HCV Enzyme Immunoassay. Descriptive analyses were performed based on the Guide to Demographic Health Survey statistics. We applied sample weighting to derive representative estimates. Of the total tested, more than half (54.40%) were aged 15–29 years and 51.59% were women. Overall HCV seroprevalence was 0.18% (95% Confidence Interval: 0.10–0.32). Higher seroprevalences were found in Afar (0.92%) and South Nations Nationality Peoples Region (0.43%); people living with HIV (PLWH) (0.62%); the poorest wealth index (0.35%); people having multiple lifetime sexual partners (0.31%); and widowed/divorced individuals (0.30%). In stratified analyses by sex and residency, we found higher seroprevalences in non‐Christian and non‐Muslim males (1.98%) and rural population (1.00%), male PLWH (1.67%), rural PLWH (1.45%), widowed/divorced males (0.97%), and in all groups from the Afar region: males (1.30%), females (0.61%), urban (1.07%), and rural (0.86%). HCV seroprevalence among the general population in Ethiopia is much lower than from previous estimates. General population screening is unlikely to be cost‐effective, and so screening programs targeted to people at greater risk of HCV will be required.

## Full-text entities

- **Diseases:** Hepatitis C (MESH:D019698)
- **Species:** Hepatitis C virus [taxon 11103], Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11883455/full.md

---
Source: https://tomesphere.com/paper/PMC11883455